NervGen Pharma Corp. reported unaudited financial results for the six months ended June 30, 2026, showing a net loss of CA$30.9 million compared to CA$13.1 million in the prior year period. Cash and cash equivalents increased significantly to CA$86.8 million from CA$22.1 million at year-end 2025, driven by gross proceeds of CA$82.9 million (US$60.0 million) from an underwritten public offering closed on May 22, 2026. The company also initiated a new ATM equity program on Nasdaq in July 2026 following the termination of its previous TSX Venture Exchange program. Operating expenses rose to CA$19.7 million, with research and development spending nearly doubling to CA$12.8 million as the company prepares for Phase 3 clinical trials of its lead candidate NVG-291 for spinal cord injury. NervGen Pharma Corp. operates in the biotechnology industry, focusing on the discovery and development of neuroreparative therapeutics.

NervGen Pharma Corp. entered into a Sales Agreement with Leerink Partners LLC on July 2, 2026. The company operates in the biotechnology industry and develops therapies for neurodegenerative diseases.